Aditum forms new company for China-sourced asset in $1B deal

Aditum has established another new company ('newco') centered around an asset sourced from China as part of a deal valued at $1 billion1.

The Chinese-derived asset is related to therapeutic areas including dyslipidemia and vascular disorders, and the deal involves Mabwell, a Chinese biopharma company1.

This move highlights the increasing trend of major cross-border licensing and asset transfers in the pharmaceutical sector, particularly involving Chinese biotech firms and global commercialization partnerships3.

Such deals often involve investors backing these new entities to advance development, with intentions to sell or form larger partnerships as the asset matures5.

China’s role in global biopharma transactions has grown rapidly, with deal values and volume accelerating significantly in recent years3.

Sources:

1. https://firstwordpharma.com/river/top-stories

3. https://www.ecinnovations.com/blog/chinas-biopharma-boom-in-global-drug-licensing-deals/

5. https://www.jdsupra.com/legalnews/key-trends-and-considerations-in-cross-2062466/